Using anti-angiogenic agents in advanced gastric and esophagogastric adenocarcinomas Annual Meeting GI 2016

Daniel Catenacci, MD of The University of Chicago Medicine discusses using anti-angiogenic agents in advanced gastric and esophagogastric adenocarcinomas at ASCO GI 2016

Advertisement Single Below Content

Using anti-angiogenic agents in advanced gastric and esophagogastric adenocarcinomas Annual Meeting GI 2016

Advancing Acute Lymphoblastic Leukemia Treatment with CAR-T Cells: Insights from Dr. Anjali Advani

Advances in Acute Lymphoblastic Leukemia (ALL) Treatment: A Focus on Targeted Therapies – Elias Jabbour, MD

FDA grants accelerated approval to ponatinib (ICLUSIG®) with chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia

Using anti-angiogenic agents in advanced gastric and esophagogastric adenocarcinomas Annual Meeting GI 2016

Related Posts

Advancing Acute Lymphoblastic Leukemia Treatment with CAR-T Cells: Insights from Dr. Anjali Advani

Advances in Acute Lymphoblastic Leukemia (ALL) Treatment: A Focus on Targeted Therapies – Elias Jabbour, MD

FDA grants accelerated approval to ponatinib (ICLUSIG®) with chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia